Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Assistant Professor of Medicine

University of Maryland
Baltimore, Maryland

Clinician Investigator
DC partnership for AIDS Progress

Topics of Professional Interest:
  • HIV co-infections with hepatitis C virus and B virus
  • HCV therapeutics
  • HCV natural history and outcomes
Current Professional Summary:

Dr Anu Osinusi is an assistant professor of medicine in the Division of Infectious Diseases, Department of Medicine at the University of Maryland where she focuses on viral hepatitis coinfection in HIV infected patients. 

She also serves as the clinical director of the DC Partnership for AIDS Progress (DCPFAP) hepatitis program where she provides clinical care and management of hepatitis infections in DC community clinics while conducting clinical and translational research at the National Institute of Allergy and Infectious Diseases (NIAID).

Committees and Organizations:
  • Infectious Diseases Society of America (2010-present)
  • American Association for the Study of Liver Diseases (2010-present)
  • College of Medicine University of Ibadan, Nigeria, MBBS (MD) in Medicine (2000)
  • University of College Hospital, Ibadan, Nigeria, Rotating Internship (2001)
  • Harvard School of Public Health, Boston,  MPH (2002)
  • Rush University Medical Center Residency in Internal Medicine (2007)
  • University of Maryland, Baltimore, Fellowship in Infectious Diseases (2010)
Selected Publications:
  1. A. Osinusi, M. McLaughlin, M.A. Polis, S. Kottilil. HIV/HCV Co-Infected Virologic Responders To Pegylated IFN And Ribavirin Therapy More Frequently Suffer IFN-Related Adverse Events. J Acquir Immune Defic Syndr. 2010 Mar 1;53(3):357-63.
  2. Jean K. Carr, Anu Osinusi, Colin P. Flynn, et al. Two independent epidemics of HIV in Maryland. J Acquir Immune Defic Syndr. 2010 May 26
  3. Murphy AA, Herrmann E,  Osinusi A et al. Twice Weekly Peg-IFN-alpha-2a and Ribavirin results in superior viral kinetic response in HIV/HCV Co-infected African American Patients Compared to Standard Treatment. AIDS. 2011 Jun 1;25(9):1179-1187.
  4. Osinusi A, Naggie S, Poonia S et al. ITPA Gene Polymorphisms Significantly Affect Hemoglobin Decline and Treatment Outcomes in HIV/HCV Co-infected Patients. J Med Virol. 2012 Jul;84(7):1106-14. -7
  5. Naggie S, Osinusi A, Katsounas A, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology. 2012 Aug;56(2):444-54.
  6. Anu Osinusi, Aarthi Chary, Mark A. Winters, et al. IL28B  Polymorphism is Not Associated with HCV Protease Diversity in HIV/HCV Co-infected Patients Treated with Pegylated Interferon and Ribavirin. J Med Virol. 2012 Oct;84(10):1522-7
  7. D. Silver, G. Karnik, A. Osinusi, et al. Effect of HIV on Liver Fibrosis among HCV-Infected African Americans. Clinical Infectious Diseases. 2013
  8. Anuoluwapo Osinusi, Susanna Naggie. Boceprevir for HCV in patients with HIV: where next? The Lancet Infectious Diseases. 2013: July 3
  9. Anuoluwapo Osinusi,Eric G.Meissner ,Yu-Jin Lee et al Efficacy Of Sofosbuvir And Ribavirin For Treatment Of Hepatitis C Genotype-1 In A Traditionally Difficult To Treat Population : A Randomized Controlled Trial. JAMA. 2013 (In press)


An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management